ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Signatera Altera & Empower Patient Card
Read More
-
Dr. Abhinand Peddada - Signatera for HNSCC early intervention
Watch Video
-
Signatera Genome: Unlocking the next level of ultrasensitive MRD detection with Phased Variant technology
Watch Video
-
Meet Marci, Invasive Lobular Breast Cancer Survivor and Signatera™ Patient
Read Article
-
Signatera Explainer
Watch Video
-
Partnering in Survivorship: The Oncology-OB/GYN connection in breast cancer surveillance
Watch Video
-
Signatera MRD Testing for NSCLC Patient Management
Watch Video
-
Personalized ctDNA testing in Urothelial Cancer
Watch Video
-
ASH 2025 Signatera Data Highlights
Read More
-
Signatera™ MRD Testing for Head and Neck Cancer
Watch Video
-
New data. Better insight. The future of precision breast cancer management
Watch Video
-
Pan-Lymphoma Analysis Brochure
Read More
-
Understanding Signatera™ for Testicular Cancer
Read Article
-
An MRD-guided approach to advancing treatment strategies in gynecologic cancer
Watch Video
-
Shaping the future of skin cancer: Tumor-informed ctDNA-guided interventions
Watch Video
-
Understanding the SINERGY Trial: A More Personalized Approach to Treating Head & Neck Cancer
Read Article
-
From Detection to Decision-Making: Utility of Signatera in Complex GI & Hepatobiliary Malignancies
Watch Video
-
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in
Ma VT., Zhou AY., Forati A., et al. JCO PO 2026
Read More
-
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma
Ansstas G., Khaddour K., Sudhaman S., et al. CCR. 2026
Read More
-
Loading More...
